The progress of predictive value of Ki-67 and traditional biomarkers for sensitivity to adjuvant chemotherapy in breast cancer

Breast cancer is the most common cancer in women.The proliferation antigen Ki-67,oestrogen receptors(ER) and progesterone receptors(PR) and CerbB-2 are currently used in routine pathological assessment of breast cancer.Several studies have confirmed that over-expression of Ki-67 in breast cancer canpredict higher sensitivity to chemotherapy.ER and PR have their greatest utility in predicting response to hormonal therapy.Some studies have demonstrated thatthey can predict the response to chemotherapy.The absense of CerbB-2 in brea-st cancer has been shown to predict for improved response to chemotherapy.W e review the previous studies on the predictive value of these biomarkers for response to adjuvant chemotherapy in breast cancer.